other material
confidence high
sentiment positive
materiality 0.55
Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors
CITIUS ONCOLOGY, INC.
- 27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.
- Median progression-free survival of 57 weeks (range 30-96 weeks) for patients achieving clinical benefit.
- Combination was well-tolerated with no documented ≥Grade 3 immune-related adverse events; one dose-limiting toxicity (capillary leak) at 12 mcg/kg.
- Two of four partial responders had failed prior anti-PD-1 therapy, suggesting potential to overcome checkpoint resistance.
- Trial nearing completion with three additional patients to enroll; data presented at SITC 2024.